What is GRCE's health score?

Grace Therapeutics, Inc. (GRCE) has a TradeApes health score of 46 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is GRCE's estimated fair value?

Based on our 5-year discounted cash flow model, Grace Therapeutics, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is GRCE undervalued or overvalued?

Our model currently rates GRCE as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

1 free score card remaining

Grace Therapeutics, Inc. (GRCE)

Healthcare Inconclusive inconclusive mixed

$2.47

Updated: 2026-07-18

TradeApes Score

Financial Strength

50 Mixed

Operating Trend

50 Mixed

Relative Value

40 Weak

Capital Allocation

30 Weak

Risk Management

65 Healthy

Key Findings

+ Strong FCF growth — free cash flow up more than 20% year over year

Unlock Full Report →

− Significant dilution — share count up more than 5% year over year

Unlock Full Report →

Industry Related Stocks

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Aardvark Therapeutics, Inc. (AARD) Abivax S.A. (AAVXF) Ascend Wellness Holdings, Inc. (AAWH) AbbVie Inc. (ABBV) AbCellera Biologics Inc. (ABCL)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.